Background Mosunetuzumab is a CD20× CD3 T-cell-engaging bispecific monoclonal
antibody that redirects T cells to eliminate malignant B cells. In a phase 1 study …

Dendritic cells (DCs) are immune specialized cells playing a critical role in promoting
immune response against antigens, and may represent important targets for therapeutic …

The type II anti-CD20 antibody obinutuzumab has structural and mechanistic features that
distinguish it from the first anti-CD20 antibody, rituximab, which have translated into …

Diagnosis should be based on a surgical specimen/excisional lymph node (LN) biopsy.
Core biopsies should only be carried out in patients without easily accessible LNs (eg …

Patients with follicular lymphoma (FL) frequently require multiple treatments during their
disease course; however, survival based on lines of treatment remains poorly described in …

PURPOSE We compared 2 years of rituximab maintenance (RM) with a response-adapted
postinduction approach in patients with follicular lymphoma who responded to induction …

Background Novel therapies for relapsed or refractory follicular lymphoma are commonly
evaluated in single-arm studies without formal comparison with other treatments or historical …

Large B-cell lymphoma of immune-privileged sites (LBCL-IP) arise in immune sanctuaries
including the testis and central nervous system (CNS). After initially reaching complete …

The COVID‐19 pandemic poses a unique challenge to the care of patients with
haematological malignancies. Viral pneumonia is known to cause disproportionately severe …

Axicabtagene ciloleucel (axi-cel) is an autologous anti-CD19 chimeric antigen receptor
(CAR) T-cell therapy approved for relapsed/refractory (R/R) follicular lymphoma (FL) …